Navigation Links
Promising new TB drug given special status by US and European regulators
Date:10/25/2007

What: Approximately one-third of the worlds population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005. Currently, TB patients must adhere to a complex treatment regimen over a six- to nine-month period. This demanding schedule often results in patients skipping treatment doses, which has given rise to drug-resistant strains of M. tuberculosis, including multi-drug-resistant (MDR) and, more recently, extensively drug-resistant (XDR) TB.

SQ109, an antimicrobial agent developed through a partnership between the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and the biotech company Sequella, Inc., has recently been granted orphan drug status by the U.S. Food and Drug Administration and the European Medicines Agency for development against drug-susceptible and drug-resistant TB. This orphan designation will help accelerate clinical testing of the drug; SQ109 (in combination with other TB drugs) may help establish simpler and more effective treatment regimens for the disease.

Recent events have underscored the immense problem of antimicrobial resistance, including the growing threat of MDR-TB, according to NIAID Director Anthony S. Fauci, M.D. The advancement of SQ109 to a clinical candidate, he says, demonstrates the key role that public-private partnerships can play in developing new interventions to improve public health.

SQ109 was discovered by NIAID scientists in 1999 and developed with grant and contract support from NIAID and contributions by the National Cancer Institute/NIAID Inter-Institute Program for the Development of AIDS-related Therapeutics. NIAID licensed the SQ109 technology to Sequella in March 2006 under a Cooperative Research and Development Agreement.


'/>"/>

Contact: NIAID News and Public Information Branch
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology: